CASI Pharmaceuticals, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & Equivalents | $5.6M | $13.5M | $17.1M | $47.1M | $38.7M |
| Accounts Receivable | $4.1M | $15.3M | $9.6M | $13.0M | $9.8M |
| Inventory | $1.6M | $5.3M | $15.9M | $6.1M | $1.9M |
| Total Current Assets | $13.5M | $39.6M | $59.3M | $73.4M | $62.0M |
| Property, Plant & Equipment | $7.0M | $7.9M | $9.2M | $11.8M | $12.7M |
| Goodwill | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | $221.0K | $238.0K | $1.8M | $1.1M | $12.2M |
| Total Assets | $25.7M | $53.7M | $75.3M | $96.2M | $138.3M |
| Liabilities | |||||
| Accounts Payable | $1.1M | $2.7M | $4.4M | $3.3M | $2.2M |
| Total Current Liabilities | $49.7M | $36.5M | $16.7M | $17.0M | $13.2M |
| Long-Term Debt | — | — | $18.9M | — | — |
| Total Liabilities | $62.9M | $51.8M | $51.1M | $29.3M | $30.3M |
| Stockholders' Equity | |||||
| Retained Earnings | $-748.1M | $-700.1M | $-660.8M | $-637.2M | $-605.6M |
| Total Stockholders' Equity | $-37.3M | $1.9M | $24.2M | $44.6M | $84.5M |